Lexicon Pharmaceuticals
Manufacturing · Texas, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2445 Technology Forest Blvd Fl 11, The W...Phone Number
(281) 863-3000Website
www.lexpharma.comRevenue
$69.6 MillionStock Symbol
LXRXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
5
1
1
1
1
1
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectively treat disease and improve patient lives.Explore more
Lexicon Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lexicon Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Lexicon Pharmaceuticals launches new products
Earning: See what the market has to say on Lexicon Pharmaceuticals recently announced quarterly report
Lexicon Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Lexicon Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Lexicon Pharmaceuticals
Funding: Get notified immidiatlly once Lexicon Pharmaceuticals has new funding data
Click to see if Lexicon Pharmaceuticals had a recent Job posting/layoffs
Check if Lexicon Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Lexicon Pharmaceuticals
Find more new buyers
Compare Similar Companies to Lexicon Pharmaceuticals
Compare insights from companies similar to Lexicon Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Lexicon Pharmaceuticals
$69.6M
51-200
Public
$1.5B
1995
Scott CoianteSenior Vice President & Chief Financial Officer
Company Profile Activity
Activity Insights
Lexicon Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lexicon Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals financials insights
Gather financial insights about Lexicon Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Stock Offering
$55.2M
2010
Stock Offering
$181.4M
2012
Stock Offering
$37.2M
2014
Multiple Rounds
$273.7M
2017
Debt
$200M
2022
Debt
$150M
2026
Private Equity
$55.7M
Lexicon Pharmaceuticals Tech Stack
A closer look at the technologies used by Lexicon Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Lexicon Pharmaceuticals has announced a successful end of Phase II meeting with the FDA for pilavapadin in diabetic peripheral neuropathic pain, receiving guidance that supports commitment to a Phase III program, with the FDA formally recognizing pilavapadin's lack of addiction potential a significant distinction in a therapeutic area where oral opioids account for approximately 20% of the current treatment regimen.
Pharmaceuticals, Clinical Operations
Project
Lexicon Pharmaceuticals has launched a water heater product line through its Ariston partnership, with the launch reported to have exceeded expectations, positioning the company ahead of 2029 regulations that will require heat pump integration in all water heaters above 35 gallons.
Project
Lexicon Pharmaceuticals has announced that its SONATA Phase III trial, a 500-patient study evaluating sotagliflozin in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM), is on track to complete enrollment by mid-year, with screening at study sites set to stop on June 19th. This milestone positions Lexicon Pharmaceuticals to deliver trial data in Q1 of next year, in line with previously communicated guidance.
Pharmaceuticals, Clinical Operations
Project
Lexicon Pharmaceuticals has announced plans to resubmit sotagliflozin, under the brand name ZYNQUISTA, to the FDA for glycemic control in Type 1 diabetes by mid-year, in collaboration with the Steno Group of Denmark, which is providing new prospective data on DKA exposure rates that the FDA has confirmed would be acceptable as part of the submission.
Medical Research, Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lexicon Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Lexicon Pharmaceuticals is a biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectivel... Read More
